The TRAIL apoptotic pathway in cancer onset, progression and therapy

被引：714

作者：

Johnstone, Ricky W. ^{[1
]}

Frew, Ailsa J. ^{[1
]}

Smyth, Mark J. ^{[1
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia

来源：

NATURE REVIEWS CANCER | 2008年 / 8卷 / 10期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nrc2465

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triggering of tumour cell apoptosis is the foundation of many cancer therapies. Death receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized, as have the signals that are generated when these receptors are activated. TNF-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility of recombinant TRAIL and agonistic antibodies against TRAILR1 and TRAILR2.

引用

页码：782 / 798

页数：17

共 216 条

[101] Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 [J].

MacFarlane, M ;

Inoue, S ;

Kohlhaas, SL ;

Majid, A ;

Harper, N ;

Kennedy, DBJ ;

Dyer, MJS ;

Cohen, GM .

CELL DEATH AND DIFFERENTIATION, 2005, 12 (07) :773-782

[102] Association of a common variant of the CASP8 gene with reduced risk of breast cancer [J].

MacPherson, G ;

Healey, CS ;

Teare, MD ;

Balasubramanian, SP ;

Reed, MWR ;

Pharoah, PDP ;

Ponder, BAJ ;

Meath, M ;

Bhattacharyya, NP ;

Cox, A .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (24) :1866-1869

[103] Augmented antitumor activity against B-Cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20 [J].

Maddipatla, Sreeram ;

Hernandez-Ilizaliturri, Francisco J. ;

Knight, Joy ;

Czuczman, Myron S. .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4556-4564

[104] AKT/PKB signaling: Navigating downstream [J].

Manning, Brendan D. ;

Cantley, Lewis C. .

CELL, 2007, 129 (07) :1261-1274

[105] A novel receptor for Apo2L/TRAIL contains a truncated death domain [J].

Marsters, SA ;

Sheridan, JP ;

Pitti, RM ;

Huang, A ;

Skubatch, M ;

Baldwin, D ;

Yuan, J ;

Gurney, A ;

Goddard, AD ;

Godowski, P ;

Ashkenazi, A .

CURRENT BIOLOGY, 1997, 7 (12) :1003-1006

[106] A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells [J].

Martelli, AM ;

Tazzari, PL ;

Tabellini, G ;

Bortul, R ;

Billi, AM ;

Manzoli, L ;

Ruggeri, A ;

Conte, R ;

Cocco, L .

LEUKEMIA, 2003, 17 (09) :1794-1805

[107]

Martinez-Ferrandis Jose I., 2007, Cancer Biomarkers, V3, P89

[108] Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy [J].

McCubrey, J. A. ;

Steelman, L. S. ;

Abrams, S. L. ;

Bertrand, F. E. ;

Ludwig, D. E. ;

Baesecke, J. ;

Libra, M. ;

Stivala, F. ;

Milella, M. ;

Tafuri, A. ;

Lunghi, P. ;

Bonati, A. ;

Martelli, A. M. .

LEUKEMIA, 2008, 22 (04) :708-722

[109] Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2 [J].

Merino, Delphine ;

Lalaoui, Najoua ;

Morizot, Alexandre ;

Schneider, Pascal ;

Solary, Eric ;

Micheau, Olivier .

MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (19) :7046-7055

[110] Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells [J].

Meurette, Olivier ;

Fontaine, Anne ;

Rebillard, Amelie ;

Le Moigne, Gwenaelle ;

Lamy, Thierry ;

Lagadic-Gossmann, Dominique ;

Dimanche-Boitrel, Marie-Therese .

SIGNAL TRANSDUCTION PATHWAYS, PT A: APOPTOTIC AND EXTRACELLULAR SIGNALING, 2006, 1090 :209-216

← 6 7 8 9 10 11 12 13 14 15 →